LPTX - Leap Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

39.73M

Cash

102M

Avg Qtr Burn

-12.56M

Short % of Float

9.13%

Insider Ownership

8.28%

Institutional Own.

33.60%

Qtr Updated

03/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
DKN-01 (+/- Paclitaxel) Details Cancer, Carcinosarcoma, Ovarian cancer, Endometrial cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DKN-01 (Bevacizumab & Chemotherapy) Details Cancer, Colorectal cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DKN-01 (+ tislelizumab +/- CAPOX) Details Gastroesophageal junction tumors, Cancer, Gastric cancer	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FL-301 Details Cancer, Pancreatic cancer, Gastric cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DKN-01 monotherapy or in combination with docetaxel Details Prostate cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.